Research programme: anti-RSV monoclonal antibodies - Biolex

Drug Profile

Research programme: anti-RSV monoclonal antibodies - Biolex

Alternative Names: Anti-RSV antibodies research programme - Biolex; R-19

Latest Information Update: 16 Apr 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biolex
  • Developer Biolex; Dow Chemical
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 03 Jul 2012 Biolex files for Chapter 7 bankruptcy in the US Bankruptcy Court for the Middle District of North Carolina
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 31 May 2002 Dow Chemical Company has started growing the first greenhouse plant lines to yield the RSV antibody product R-19
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top